港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

728.939

-15.659-2.10%

涨家数：14

跌家数：18

平家数：2

市盈率：- -

高：744.967

开：744.496

低：723.794

收：744.598

数据加载中...

制药企业将被转卖给大基金

CRO的局部复苏

中国医药创新促...

10亿，华润押注创新药

启明医疗-B盘中异动下午盘快速上涨5.19%报2.840港元

港股异动 | 思派健康(00314.HK)午后涨超10% 超百款药品申报商保创新药目录公司深度聚焦商业医疗保险业务

港股异动 | 思派健康(00314)午后涨超10% 超百款药品申报商保创新药目录公司深度聚焦商业医疗保险业务

罚单落地高管闪电辞任，广济药业连亏困局待解

康方生物(09926)涨超6% 核心产品依沃西有新进展机构指公司创新药产品疗效优秀

港股异动 | 医药股多数走强国家医保局明确药品集采“反内卷”机构称板块估值仍具有吸引力

智通财经网

港股异动 | 微创系午后走高微创医疗(00853.HK)飙升逾23% 心通医疗-B(02160.HK)现涨超6%

华润山东医药等六公司中标东营市人民医院药品配送项目

科济药业-B盘中异动下午盘快速拉升5.03%

港股康希诺拉升涨近14%

港股异动 | 康希诺生物涨超13%，成交额超1.8亿港元

老虎资讯综合

歌礼制药-B大涨5.32% 近日完成ASC47与司美格鲁肽联合使用的28例肥胖受试者给药

歌礼制药-B盘中异动下午盘大幅拉升5.32%报11.080港元

基石药业-B盘中异动下午盘急速上涨5.20%

东曜药业-B盘中异动股价大涨5.14%

康诺亚-B盘中异动大幅拉升5.00%

上海浦东：支持进口创新药全球首发产品落地推动100个进口产品实现本地生产

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=7"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":728.93866,"timestamp":1753430886241,"preClose":744.5975,"halted":0,"volume":295989198,"delay":0,"changeRate":-0.02103,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-15.658813,"latestTime":"07-25 16:00:00","open":744.49634,"high":744.967,"low":723.794,"amount":7101826928,"amplitude":0.028435,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"pbRate":5.862148,"peRate":-36.113023,"turnoverRate":0.011111,"increases":13,"decrements":20,"flats":0,"marketCap":427345468672,"floatMarketCap":392843141040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":744.967,"amplitude":0.028435,"preClose":744.5975,"low":723.794,"pbRate":"5.862148","latestPrice":728.93866,"volume":295989198,"delay":0,"open":744.49634,"prevYearClose":331.1933,"prevWeekClose":711.682,"prevMonthClose":555.617,"prevQuarterClose":555.617,"fiveDayClose":711.682,"twentyDayClose":566.494,"sixtyDayClose":466.153,"secType":"PLATE","market":"HK","turnoverRate":0.011111,"peRate":-36.113023,"marketCap":427345468672,"floatMarketCap":392843141040,"timestamp":1753430886241,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":18,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553272789","title":"制药企业将被转卖给大基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2553272789","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553272789?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 15:25","pubTimestamp":1753341900,"startTime":"0","endTime":"0","summary":"制药巨头Gland Pharma可能被以214亿转卖。该公司由PVN Raju创立，是复星医药控股子公司，业务覆盖全球60国，近年还布局了复杂注射制剂及生物药CDMO业务。尽管复星医药逐渐减持Gland Pharma股份，但依然保持控股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724155724971b8cc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724155724971b8cc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","01477","BK1593","02196","BK1191","BK1574","600196"],"gpt_icon":0},{"id":"2553720942","title":"CRO的局部复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2553720942","media":"中国医药创新促...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553720942?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 15:23","pubTimestamp":1753341825,"startTime":"0","endTime":"0","summary":"而在创新药企取得成果之后，复苏传导至CRO，往往存在时间差。所以比起2021年前的全民盛宴，这更像是一场局部的复苏。因此，CRO的“复苏”必须加上苛刻的定语：仅限于头部 CRO 中押对最新 BD 风向的部门，以及拥有独家适应症优势或技术平台的小而美 CRO，其余同质化的CRO依旧吃不饱。长期来看，无论是Biotech还是CRO，专注于自身最擅长、最有资源禀赋的细分领域，形成差异化优势，对行业整体健康发展更为有利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724155320a6bf2a07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724155320a6bf2a07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","603259","BK1141","BK1574","BK1576","03347","BK1161","02359","06978"],"gpt_icon":0},{"id":"2553274367","title":"10亿，华润押注创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2553274367","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553274367?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 15:10","pubTimestamp":1753341046,"startTime":"0","endTime":"0","summary":"对于华润而言，此次参与创新投资基金的设立，是其在创新转型道路上的重要一步。通过整合各方资源，华润医药将进一步优化战略布局，提升在医药创新领域的核心竞争力。复星医药作为国内医药行业的领军企业，此次携手华润医药，不仅是双方在业务领域的深度合作，更是对医药创新未来的一次战略性布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072415181894b7be2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072415181894b7be2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348825331.USD","LU0501845795.SGD","BK1240","LU0880133367.SGD","IE0008368742.USD","LU0048597586.USD","LU1880383366.USD","LU0979878070.USD","LU0173614495.USD","LU0594300419.USD","LU0605514214.HKD","LU0072913022.USD","LU0067412154.USD","LU0738912210.USD","LU2088748293.HKD","LU2088747998.USD","BK1570","LU0370786039.SGD","LU1807302812.USD","LU0359201612.USD","LU2088747725.USD","LU0417516902.SGD","BK1521","LU2088748376.SGD","LU1960683339.HKD","LU1152091168.USD","01109","LU0791591158.USD","BK1574","LU1023057109.AUD","LU0791590937.USD","06978","LU0516423091.SGD","LU0516422366.SGD","LU0650527681.SGD","LU1008478684.HKD","LU0251144936.SGD","LU0359202008.SGD","LU1366334578.USD","LU1152091754.HKD","LU0516423174.USD","LU0414403682.SGD","SG9999014674.SGD","LU0594300179.USD","LU0287142896.SGD","LU0516422440.USD","SG9999010052.SGD","BK1555","LU2088748020.USD","LU0516422952.EUR"],"gpt_icon":0},{"id":"2553271127","title":"启明医疗-B盘中异动 下午盘快速上涨5.19%报2.840港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553271127","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553271127?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 14:54","pubTimestamp":1753340098,"startTime":"0","endTime":"0","summary":"2025年07月24日下午盘14时54分，启明医疗-B股票出现波动，股价大幅上涨5.19%。截至发稿，该股报2.840港元/股，成交量361.45万股，换手率0.82%，振幅6.67%。资金方面，该股资金流入718.379万港元，流出251.304万港元。启明医疗-B股票所在的医疗设备及用品行业中，整体涨幅为0.56%。其相关个股中，微创医疗、春立医疗、微创机器人-B涨幅较大，振幅较大的相关个股有微创医疗、云能国际、隽泰控股，振幅分别为22.04%、17.27%、11.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724145459a6bf0d85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724145459a6bf0d85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02500","BK1583","BK1574","BK1100"],"gpt_icon":0},{"id":"2553271567","title":"港股异动 | 思派健康(00314.HK)午后涨超10% 超百款药品申报商保创新药目录 公司深度聚焦商业医疗保险业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2553271567","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553271567?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 14:49","pubTimestamp":1753339769,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159992","BK1247","BK1574","BK1161","00314","06978"],"gpt_icon":0},{"id":"2553271560","title":"港股异动 | 思派健康(00314)午后涨超10% 超百款药品申报商保创新药目录 公司深度聚焦商业医疗保险业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2553271560","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553271560?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 14:49","pubTimestamp":1753339769,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，思派健康午后涨超10%，截至发稿，涨9.03%，报6.76港元，成交额9775.01万港元。目前一共有超过100个药品申报了创新药目录，接下来国家医保局会按程序做好后续工作。据悉，4月24日，复星联合健康保险与思派健康在上海正式签署战略合作协议。6月26日，思派健康与国际保险服务集团安睿嘉尔签订战略合作协议。此外，随着商业医疗保险渗透率提升和创新药市场扩容，公司独特的生态闭环价值有望获得更充分定价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06978","159992","00314","BK1161","BK1247"],"gpt_icon":0},{"id":"2553279048","title":"罚单落地高管闪电辞任，广济药业连亏困局待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2553279048","media":"蓝鲸财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553279048?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 14:36","pubTimestamp":1753338985,"startTime":"0","endTime":"0","summary":"此时距离他收到湖北证监局80万元罚单，仅过去19天。财务魔术的代价调查显示，2022年1月至9月，济康医药在部分经销业务中扮演的实为“中介”角色，却将自己包装成“货主”。这种会计手法魔术，让广济药业2022年一季报、半年报、三季报营收分别虚增25.49%、26.68%、20.49%。尽管通过精简部门、裁减生产人员实现“减亏”，但二级市场并不买账。断腕求生的资产腾挪为回血聚焦主业，广济药业近期悄然完成一笔资产剥离。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1753239527719150741","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2553279810","title":"康方生物(09926)涨超6% 核心产品依沃西有新进展 机构指公司创新药产品疗效优秀","url":"https://stock-news.laohu8.com/highlight/detail?id=2553279810","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553279810?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 14:13","pubTimestamp":1753337599,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康方生物 午后发力走高，截至发稿，报152.4港元，涨幅6.28%，成交额15.32亿港元。依沃西联合化疗联合/不联合莱法利有望填补治疗转移性胰腺癌一线免疫疗法的空白。中信建投研报指，康方生物作为全球双抗引领者，其核心产品依沃西成为全球首个在1L肺癌治疗中mPFS超越K药的双抗，海外HARMONi数据延续国内获益趋势，验证了依沃西在跨区域研究中具有一致性的临床疗效。考虑到公司创新药产品疗效优秀、市场空间广阔，给予“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1962814","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","LU1794554557.SGD","06978","IE00B5MMRT66.SGD","LU1720050803.USD","IE00BPRC5H50.USD","LU2488822045.USD","BK1574","159992","IE00B543WZ88.USD","BK1161","09926","LU0348784397.USD","LU0348783233.USD"],"gpt_icon":0},{"id":"2553276948","title":"港股异动 | 医药股多数走强 国家医保局明确药品集采“反内卷”机构称板块估值仍具有吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2553276948","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553276948?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:52","pubTimestamp":1753336377,"startTime":"0","endTime":"0","summary":"中信建投证券表示，看好具有严格质量体系、具有规模成本优势、获得临床认可和广泛使用的产品在集采中维持甚至扩大市场份额。光大证券指出，港股医药板块估值收缩已持续数年，部分优质企业PE估值在反弹后仍具吸引力。考虑到部分创新药公司BD交易持续催化、细分赛道及正处于转型阶段的公司或有积极变化，该行认为应当积极关注板块高质量标的、增加板块配置。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","09939","159938","BK1574","BK1161"],"gpt_icon":0},{"id":"2553276988","title":"港股异动 | 微创系午后走高 微创医疗(00853.HK)飙升逾23% 心通医疗-B(02160.HK)现涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553276988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553276988?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:52","pubTimestamp":1753336335,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","BK1574","BK1583","BK1589","BK1617","02252","BK1585","02172","00853","02160"],"gpt_icon":0},{"id":"2553276150","title":"华润山东医药等六公司中标东营市人民医院药品配送项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2553276150","media":"DoNews","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553276150?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:34","pubTimestamp":1753335243,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年07月23日，东营市人民医院发布药品集中配送服务商遴选招标项目中标结果公告。此次招标由东营市人民医院发起，最终确定的中标供应商包括华润山东医药有限公司、瑞康医药集团股份有限公司、上药控股东营有限公司、山东康诺盛世医药有限公司、国药控股东营有限公司以及东营九州通医药有限公司。本次公告类型为中标结果公告，项目代理机构为山东金卫医药信息有限公司。公告期限为自发布之日起1个工作日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072413344594b79206&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072413344594b79206&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU1152091754.HKD","LU1993786604.SGD","LU0287142896.SGD","LU2088748020.USD","LU1366334651.USD","LU0067412154.USD","LU0594300179.USD","BK1570","09939","LU2088747998.USD","LU0417516902.SGD","SG9999010078.USD","LU0516422440.USD","SHPMY","LU0979878070.USD","02607","LU0605514214.HKD","LU0048597586.USD","LU0516423174.USD","BK1589","BK1574","IE0008368742.USD","LU0359201612.USD","LU0516422952.EUR","SG9999009997.SGD","LU0348825331.USD","LU1242518857.USD","SG9999010052.SGD","LU0414403682.SGD","SHTDY","LU0791590937.USD","LU0516422366.SGD","601607","LU1366334578.USD","LU0880133367.SGD","LU0791591158.USD","LU1242518931.SGD","LU0251144936.SGD","03320","LU0173614495.USD","LU0594300419.USD","LU0048580855.USD","LU0370786039.SGD","LU2088747725.USD","LU1960683339.HKD","LU0359202008.SGD","BK1240","01109","LU0501845795.SGD","01099","LU1008478684.HKD","LU0516423091.SGD","LU0650527681.SGD","LU1807302812.USD","BK1521"],"gpt_icon":0},{"id":"2553761602","title":"科济药业-B盘中异动 下午盘快速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553761602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553761602?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:32","pubTimestamp":1753335174,"startTime":"0","endTime":"0","summary":"2025年07月24日下午盘13时32分，科济药业-B股票出现异动，股价快速上涨5.03%。机构评级方面，在所有2家参与评级的机构中，50%的券商给予买入建议，50%的券商给予卖出建议，无券商给予持有建议。科济药业-B股票所在的生物技术行业中，整体涨幅为1.67%。其相关个股中，康希诺生物、中国抗体-B、圣诺医药-B涨幅较大，振幅较大的相关个股有奥星生命科技、同源康医药-B、迈博药业-B，振幅分别为24.18%、19.45%、17.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724133254971b4ea6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724133254971b4ea6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02171","BK1587","BK1574","BK1585"],"gpt_icon":0},{"id":"2553027521","title":"港股康希诺拉升涨近14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553027521","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553027521?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:32","pubTimestamp":1753335135,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"304dad910e5a201f2162ce5c4cebbba9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0348783233.USD","01672","HSTECH","IE00BPRC5H50.USD","BK1515","BK0239","LU1794554557.SGD","BK4614","07226","BK1191","BK1161","LU1720050803.USD","LU0348784397.USD","HSCEI","LU2488822045.USD","IE00B5MMRT66.SGD","159837","01477","LU0417516571.SGD","YANG","09926","BK1574","IE00B543WZ88.USD","688185"],"gpt_icon":0},{"id":"1126426076","title":"港股异动 | 康希诺生物涨超13%，成交额超1.8亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126426076","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126426076?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:26","pubTimestamp":1753334795,"startTime":"0","endTime":"0","summary":"7月24日，康希诺生物盘中涨超13%，成交额超1.8亿港元。","market":"us","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"304dad910e5a201f2162ce5c4cebbba9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4614","06185","BK1161","BK1515","BK1191","BK1574"],"gpt_icon":0},{"id":"2553202493","title":"歌礼制药-B大涨5.32% 近日完成ASC47与司美格鲁肽联合使用的28例肥胖受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2553202493","media":"港美通","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553202493?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:21","pubTimestamp":1753334484,"startTime":"0","endTime":"0","summary":"7月24日13:14，歌礼制药-B(01672)上涨5.32%，该股报11.080港元，最高报11.080港元，最低报10.380港元，成交量181.49万股，成交额1931.00万港元。消息面上，歌礼制药-B近日发布公告，宣布其在美国开展的联合用药研究已完成所有28例肥胖受试者的给药。这项研究旨在评估超长效皮下注射小分子THRβ激动剂ASC47单次给药与司美格鲁肽联合使用的安全性、耐受性以及初步疗效。该临床试验于2025年5月开始入组，所有受试者在两个月内快速完成入组。预期将在2025年第四季度获得顶线数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072418392994b816ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072418392994b816ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1191","BK1574","BK1161","01672","BK1515"],"gpt_icon":0},{"id":"2553751832","title":"歌礼制药-B盘中异动 下午盘大幅拉升5.32%报11.080港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553751832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553751832?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:14","pubTimestamp":1753334082,"startTime":"0","endTime":"0","summary":"2025年07月24日下午盘13时14分，歌礼制药-B股票出现异动，股价大幅上涨5.32%。截至发稿，该股报11.080港元/股，成交量181.487万股，换手率0.19%，振幅6.65%。资金方面，该股资金流入1095.21万港元，流出612.074万港元。歌礼制药-B股票所在的生物技术行业中，整体涨幅为1.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131442a46081bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131442a46081bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1161","BK1515","BK1574","01672","BK1191"],"gpt_icon":0},{"id":"2553275133","title":"基石药业-B盘中异动 下午盘急速上涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553275133","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553275133?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:03","pubTimestamp":1753333424,"startTime":"0","endTime":"0","summary":"2025年07月24日下午盘13时03分，基石药业-B股票出现波动，股价大幅拉升5.20%。截至发稿，该股报7.280港元/股，成交量598.727万股，换手率0.41%，振幅6.94%。基石药业-B股票所在的生物技术行业中，整体涨幅为1.25%。其相关个股中，奥星生命科技、中国抗体-B、圣诺医药-B涨幅较大，振幅较大的相关个股有奥星生命科技、同源康医药-B、迈博药业-B，振幅分别为24.18%、19.45%、17.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072413034494b7851b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072413034494b7851b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2553275185","title":"东曜药业-B盘中异动 股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553275185","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553275185?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 13:03","pubTimestamp":1753333384,"startTime":"0","endTime":"0","summary":"2025年07月24日下午盘13时03分，东曜药业-B股票出现波动，股价快速上涨5.14%。截至发稿，该股报2.250港元/股，成交量36.8万股，换手率0.05%，振幅7.01%。东曜药业-B股票所在的生物技术行业中，整体涨幅为1.25%。东曜药业-B公司简介：东曜药业股份有限公司是一家临床阶段生物制药公司,主要从事开发及商业化肿瘤药物及疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724130304971b41ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724130304971b41ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"2553784322","title":"康诺亚-B盘中异动 大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553784322","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553784322?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 11:58","pubTimestamp":1753329489,"startTime":"0","endTime":"0","summary":"2025年07月24日临近午盘11时58分，康诺亚-B股票出现异动，股价大幅拉升5.00%。机构评级方面，在所有2家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。康诺亚-B股票所在的生物技术行业中，整体涨幅为0.95%。其相关个股中，奥星生命科技、中国抗体-B、圣诺医药-B涨幅较大，振幅较大的相关个股有奥星生命科技、同源康医药-B、迈博药业-B，振幅分别为24.18%、19.45%、17.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724115809a4606548&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724115809a4606548&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02162","BK1574","BK1587","BK1583","BK1161"],"gpt_icon":0},{"id":"2553201092","title":"上海浦东：支持进口创新药全球首发产品落地 推动100个进口产品实现本地生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2553201092","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553201092?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 11:09","pubTimestamp":1753326557,"startTime":"0","endTime":"0","summary":"上海市浦东新区人民政府办公室印发《浦东新区生物医药产业园区功能提升方案（2025—2027年）》。其中提出，推动外资企业延链布局。发挥外资研发中心集聚优势，支持进口创新药同步研发、同步临床、同步申报、同步上市，推动全球首发产品落地。把握跨国公司本地化生产、多产地布局等战略调整机遇，加强清单管理，持续跟踪服务，推动5个以上重点外资项目建设、100个进口产品通过多种方式实现本地生产。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/24110951943446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159992","06978","BK1574","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":32,"pageCount":7,"totalSize":640,"code":"91000000","status":"200"}]}}